Rebif’s New Formulation Delayed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Serono says it is in discussions with FDA to answer outstanding questions over the new formulation of the multiple sclerosis drug.
You may also be interested in...
Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
German drug maker's new subsidiary, Merck Serono, will oversee development of aptamer-based drugs to treat cancer.
Merck KGaA Buys Serono, Gaining U.S. Commercial Organization
Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.
Serono Says New Rebif Formulation Could Increase Tolerability
Firm files the human serum albumin-free and fetal bovine serum-free interferon beta-1a in the U.S. and the EU.